What is the price target for OPNT stock?
7 analysts have analysed OPNT and the average price target is 21.42 USD. This implies a price increase of 3.73% is expected in the next year compared to the current price of 20.65.
OPIANT PHARMACEUTICALS INC (OPNT) Forecast, Price Target & Analyst Ratings
NASDAQ:OPNT • US6837501039
Current stock price
20.65 USD
-0.12 (-0.58%)
At close:
20.75 USD
+0.1 (+0.48%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for OPIANT PHARMACEUTICALS INC (OPNT).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q4 / 2022
- EPS Estimate
- -$1.23
- Revenue Estimate
- 1.836M
Price Target Details & History
Consensus Price Target and Range
Mean target
$21.42
Upside
+ 3.73%
From current price of $20.65 to mean target of $21.42, Based on 7 analyst forecasts
Low
$21.21
Median
$21.42
High
$22.05
Price Target Revisions
1 Month
-2.33%
3 Months
-2.33%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for OPNT. The average price target is 21.42 USD. This implies a price increase of 3.73% is expected in the next year compared to the current price of 20.65.
The average price target has been revised downward by 2.33% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
45.71%
OPNT was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about OPNT.
In the previous month the buy percentage consensus was at a similar level.
OPNT was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-12-09 | Oppenheimer | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q4 / 2022
- EPS Estimate
- -$1.23
- Revenue Estimate
- 1.836M
- Revenue Q2Q
- -86.70%
- EPS Q2Q
- -1,222.00%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
63.64%
Revenue (3 Months)
63.64%
EPS (1 Month)
40.78%
EPS (3 Months)
40.78%
Next Earnings Summary
The next earnings revenue estimate has been revised upward by 63.64% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2022 - 2024
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 40.52M 189.84% | 29.63M -26.88% | 47.785M 61.27% | 9.18M -80.79% | 38.046M 314.44% | 78.183M 105.50% | |
| EBITDA YoY % growth | 10.97M 151.77% | -2.12M -119.33% | 5.251M 347.68% | N/A | N/A | N/A | |
| EBIT YoY % growth | 10.91M 151.49% | -2.24M -120.53% | 5.156M 330.19% | -42.432M -922.91% | -31.518M 25.72% | -21.318M 32.36% | |
| Operating Margin | 26.92% | -7.56% | 10.79% | -462.22% | -82.84% | -27.27% | |
| EPS YoY % growth | 2.04 157.47% | -0.46 -122.55% | 0.32 169.57% | -7.54 -2,455.56% | -3.40 54.87% | 1.49 143.78% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 22 | Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.23 -1,222.00% | -2.18 10.17% | -2.30 0.65% | 0.83 143.03% | 0.90 172.73% |
| Revenue Q2Q % growth | 1.836M -86.70% | 2.346M -47.52% | 2.04M -47.62% | 22.95M 13,099.52% | 26.826M 1,361.11% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.466M -764.52% | -10.914M 7.41% | -11.628M -2.31% | 7.14M 174.14% | 7.65M 190.36% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
66.96%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
17.51%
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
OPIANT PHARMACEUTICALS INC / OPNT Forecast FAQ
What are the consensus estimates for OPIANT PHARMACEUTICALS INC (OPNT) next earnings?
The consensus EPS estimate for the next earnings of OPIANT PHARMACEUTICALS INC (OPNT) is -1.23 USD and the consensus revenue estimate is 1.84M USD.
What is the number of analysts for OPNT stock?
The number of analysts covering OPIANT PHARMACEUTICALS INC (OPNT) is 7.